Business
CREATE Medicines Strengthens Executive Team with Appointment of Veteran Biopharma Leader Allan L. Shaw as CFO and CBO
CREATE Medicines, a clinical-stage biotechnology company pioneering RNA-based in vivo multi-immune programming, today announced the appointment of Allan L. Shaw as Chief Financial Officer (CFO) and Chief Business Officer (CBO). Mr. Shaw, an accomplished industry leader with more than 20 years of experience guiding biopharmaceutical companies through critical phases of growth, will oversee CREATE Medicines' financial strategy, capital formation, and business development initiatives as the company
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"Mr. Shaw brings more than two decades of financial, strategic, and transactional leadership to accelerate company's next phase of growth","length":140,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., Oct. 8, 2025 /PRNewswire/ -- CREATE Medicines, a clinical-stage biotechnology company pioneering RNA-based in vivo multi-immune programming, today announced the appointment of Allan L. Shaw as Chief Financial Officer (CFO) and Chief Business Officer (CBO). Mr. Shaw, an accomplished industry leader with more than 20 years of experience guiding biopharmaceutical companies through critical phases of growth, will oversee CREATE Medicines' financial strategy, capital formation, and business development initiatives as the company expands its clinical and commercial ambitions.","length":598,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/CREATE Medicines, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/CREATE Medicines, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":157,"url":"https://media.zenfs.com/en/prnewswire.com/e8139fffa70423c65140ae7429ae9084"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rZl0x_bN1XDEKyEYGnjpTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI3NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/e8139fffa70423c65140ae7429ae9084","width":400,"height":157}},"href":"https://mma.prnewswire.com/media/2789250/Create_Medicines_Logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Mr. Shaw has held senior leadership roles at numerous biopharma organizations and brings deep expertise in financing, strategic planning, and corporate development. He has served as CFO for five publicly traded companies, including Serono S.A. and Syndax Pharmaceuticals, and as a board member on seven public company boards. Over the course of his career, he has structured, negotiated, and closed more than $4 billion in public and private financings, including several IPOs, and has played a pivotal role in guiding companies from early clinical development through commercialization.","length":587,"tagName":"p"},{"type":"text","content":""Allan's appointment marks an important inflection point for CREATE Medicines as we build on our scientific leadership and prepare for the next phase of our journey," said Daniel Getts, Ph...